熱門資訊> 正文
艾伯维、Enanta宣布扩大欧盟标签，Maviret
2026-06-23 19:34
- AbbVie (ABBV) and Enanta Pharmaceuticals (ENTA) announced on Tuesday that the European Commission has approved a label expansion for their jointly developed hepatitis C therapy, Maviret.
- Accordingly, the once-daily tablet, previously available in the region only for chronic HCV infection, will also be indicated for those aged 3 years and older with the acute form of the disease, the companies said.
- Over 12M individuals in Europe suffer from infections with the hepatitis C virus, which can lead to liver complications such as cirrhosis and end-stage liver disease if left untreated, AbbVie (ABBV) said.
- The company added that the approval, backed by results from a late-stage trial for an eight-week regimen of Maviret, makes the antiviral the only HCV therapy available in the EU for acute and chronic forms of the disease.
More on AbbVie, Enanta Pharma
- AbbVie Inc. (ABBV) Apogee Therapeutics, Inc. - M&A Call - Slideshow
- AbbVie Inc. (ABBV) M&A Call Transcript
- Apogee: 'Hold' On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD
- AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis
- Apogee jumps 52% on $10.9B AbbVie buyout deal
推薦文章
華盛早報 | 存儲集體暴跌！韓媒曝英偉達Rubin產量預期下調；谷歌將躋身道指成分股；美銀力挺AI牛市至2028年
美股異動 | 科技股全線暴跌！閃迪跌超13%，美光跌超8%，邁威爾科技跌超5%
美股前瞻 | 科技股遭拋售潮！納指期貨盤前大跌2.5%；SpaceX連跌三天獲「木頭姐」狂買3200萬美元；機構稱美聯儲年內加息可能較低
新股申購 | 安克創新H股今起招股！一手入場費10032.16港元
華盛早報 | 股價三連跌市值蒸發超6000億美元！SpaceX再重挫16%；港股「ETF之王」易主！南方兩倍做多海力士年內累漲逾10倍
美股前瞻 | 萬斯稱美伊談判取得積極進展！SpaceX首度發行無抵押債券，盤前一度大跌近6%；聯電據報將與英特爾合作開發3nm芯片
「AI 教父」痛批馬斯克旗下xAI堪稱失敗，警示AI將迎巨大泡沫破裂！
美聯儲如期按兵不動，但鷹派明顯！預期年底前將加息25個基點
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
